Intravitreal topotecan
Phase 2Small molecule
Intravitreal topotecan is one of 11 small molecule programs targeting Proliferative Vitreoretinopathy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Rhegmatogenous Retinal Detachment
#DrugCompanyPhaseTrials
1Actigall
AbbVieApproved
Lovenox
SanofiPreclinical
Intravitreal topotecan
UUnity Health Toronto
Phase 2
Rhopressa
FFalcon
Preclinical
Sulfur Hexafluoride
TTurku University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intravitreal topotecan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUnity Health Toronto